Cargando…
The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline reco...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789723/ https://www.ncbi.nlm.nih.gov/pubmed/33407576 http://dx.doi.org/10.1186/s12967-020-02686-1 |
_version_ | 1783633302966501376 |
---|---|
author | Hadaegh, Farzad Asgari, Samaneh Moosaie, Fatemeh Orangi, Meysam Sarvghadi, Farzaneh Khalili, Davood Azizi, Fereidoun |
author_facet | Hadaegh, Farzad Asgari, Samaneh Moosaie, Fatemeh Orangi, Meysam Sarvghadi, Farzaneh Khalili, Davood Azizi, Fereidoun |
author_sort | Hadaegh, Farzad |
collection | PubMed |
description | BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline recommended a risk score that was calculated using pooled cohort equations (ASCVD-PCE). The guideline was updated in 2018/2019 and further risk discussion was suggested for deciding whether to continue or initiate statin therapy among non-diabetic individuals with ASCVD-PCE score ranged 5–20%. They recommended a risk discussion with considering risk enhancing factors (ASCVD-REFs) including family history of premature CVD, chronic kidney disease, triglycerides ≥ 175 mg/dl, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dl, metabolic syndrome (Mets), and for women premature menopause, and hypertensive disorders of pregnancy (HDP). In the current study, we aimed to examine the predictability of recommended ASCVD-REFs on incident hard CVD in non-diabetic individuals with LDL-C 70-189 mg/dl, with ASCVD-PCE risk 5–20% during 10 and 15-year follow-up. METHODS: Among a total of 3546 non-diabetic individuals aged 40-75 years, after excluding those with ASCVD-PCE score < 5% and ≥ 20% (n = 2342), 1204 individuals (women = 332) were included. The univariable and multivariable (further adjusted for ASCVD-PCE) Cox regression analysis were used to evaluate the association of each potential ASCVD-REFs with hard CVD. Additionnaly, the role of different components of Mets and a history of gestational diabetes (GDM)/macrosomia was also examined. The predictive ability of each significant ASCVD-REFs, then was evaluated by the discrimination accuracy and risk reclassification index. RESULTS: During the 10-year follow-up, 73 hard CVD events occurred. Although in univariable analysis, high blood pressure (BP) component of Mets, GDM/macrosomia, and HDP remained as significant ASCVD-REFs, in the multivariable analysis, only the history of HDP (5.35 (1.22–23.38)) and GDM/macrosomia (3.18 (1.05–9.65)) showed independent risks. During the 15-year follow-up, Mets (1.47 (1.05–2.06)) and its components of high waist circumference (1.40 (1.0–1.95)) and high BP (1.52 (1.07–2.15)) significantly increased the risk. These ASCVD-REFs did not improve discrimination or predictive ability. CONCLUSIONS: In a decade follow-up, only conditions specific for women and in longer follow-up, the presence of Mets perse, and its components of high WC and high BP were shown as significant ASCVD-REFs. |
format | Online Article Text |
id | pubmed-7789723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77897232021-01-07 The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study Hadaegh, Farzad Asgari, Samaneh Moosaie, Fatemeh Orangi, Meysam Sarvghadi, Farzaneh Khalili, Davood Azizi, Fereidoun J Transl Med Research BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline recommended a risk score that was calculated using pooled cohort equations (ASCVD-PCE). The guideline was updated in 2018/2019 and further risk discussion was suggested for deciding whether to continue or initiate statin therapy among non-diabetic individuals with ASCVD-PCE score ranged 5–20%. They recommended a risk discussion with considering risk enhancing factors (ASCVD-REFs) including family history of premature CVD, chronic kidney disease, triglycerides ≥ 175 mg/dl, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dl, metabolic syndrome (Mets), and for women premature menopause, and hypertensive disorders of pregnancy (HDP). In the current study, we aimed to examine the predictability of recommended ASCVD-REFs on incident hard CVD in non-diabetic individuals with LDL-C 70-189 mg/dl, with ASCVD-PCE risk 5–20% during 10 and 15-year follow-up. METHODS: Among a total of 3546 non-diabetic individuals aged 40-75 years, after excluding those with ASCVD-PCE score < 5% and ≥ 20% (n = 2342), 1204 individuals (women = 332) were included. The univariable and multivariable (further adjusted for ASCVD-PCE) Cox regression analysis were used to evaluate the association of each potential ASCVD-REFs with hard CVD. Additionnaly, the role of different components of Mets and a history of gestational diabetes (GDM)/macrosomia was also examined. The predictive ability of each significant ASCVD-REFs, then was evaluated by the discrimination accuracy and risk reclassification index. RESULTS: During the 10-year follow-up, 73 hard CVD events occurred. Although in univariable analysis, high blood pressure (BP) component of Mets, GDM/macrosomia, and HDP remained as significant ASCVD-REFs, in the multivariable analysis, only the history of HDP (5.35 (1.22–23.38)) and GDM/macrosomia (3.18 (1.05–9.65)) showed independent risks. During the 15-year follow-up, Mets (1.47 (1.05–2.06)) and its components of high waist circumference (1.40 (1.0–1.95)) and high BP (1.52 (1.07–2.15)) significantly increased the risk. These ASCVD-REFs did not improve discrimination or predictive ability. CONCLUSIONS: In a decade follow-up, only conditions specific for women and in longer follow-up, the presence of Mets perse, and its components of high WC and high BP were shown as significant ASCVD-REFs. BioMed Central 2021-01-06 /pmc/articles/PMC7789723/ /pubmed/33407576 http://dx.doi.org/10.1186/s12967-020-02686-1 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hadaegh, Farzad Asgari, Samaneh Moosaie, Fatemeh Orangi, Meysam Sarvghadi, Farzaneh Khalili, Davood Azizi, Fereidoun The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title | The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title_full | The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title_fullStr | The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title_full_unstemmed | The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title_short | The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study |
title_sort | risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: tehran lipid and glucose study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789723/ https://www.ncbi.nlm.nih.gov/pubmed/33407576 http://dx.doi.org/10.1186/s12967-020-02686-1 |
work_keys_str_mv | AT hadaeghfarzad theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT asgarisamaneh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT moosaiefatemeh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT orangimeysam theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT sarvghadifarzaneh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT khalilidavood theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT azizifereidoun theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT hadaeghfarzad riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT asgarisamaneh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT moosaiefatemeh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT orangimeysam riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT sarvghadifarzaneh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT khalilidavood riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy AT azizifereidoun riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy |